FGFR3

Across TCGA pan-cancer cohorts, FGFR3 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated FGFR3 data layer compared with 23 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher FGFR3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FGFR3 expression acts as an unfavorable survival marker, although some lineages such as SKCM and BLCA show a favorable association.

THYM, SKCM, and PRAD are the cancer types where FGFR3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	III,IV	0.103	0.944	<.001	42	view →
SKCM	DFS	Median	All	0.963	0.728	.009	10	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
ESCA	OS	Median	II,III,IV	0.216	0.702	.014	6	view →
BLCA	OS	Median	All	0.813	0.693	.036	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

FGFR3–THYM (OS)

Open the THYM breakdown →